| Date Filed | Type | Description |
| 02/10/2022 |
4
| Meswani Parag V (Chief Commercial Officer) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 153,700 restricted stock units
@ $0 |
|
| 02/10/2022 |
4
| Nassif David W. (Interim CEO, CFO) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 546,500 restricted stock units
@ $0 |
|
| 02/07/2022 |
3
| Meswani Parag V (Chief Commercial Officer) has filed a Form 3 on Sio Gene Therapies Inc. |
| 12/09/2021 |
4
| Nassif David W. (CFO) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 17,534 shares
@ $0
Paid exercise price by delivering 6,294 shares
@ $1.42, valued at
$8.9k
Disposed/sold 17,534 restricted stock units
@ $0 |
|
| 12/09/2021 |
4
| Cheruvu Pavan (CEO) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 37,567 shares
@ $0
Paid exercise price by delivering 14,884 shares
@ $1.42, valued at
$21.1k
Disposed/sold 37,567 restricted stock units
@ $0 |
|
| 04/19/2021 |
4
| Vuori Kristiina MD (Director) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 42,000 options to buy
@ $2.47, valued at
$103.7k
|
|
| 04/19/2021 |
4
| Torti Frank (Director) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 42,000 options to buy
@ $2.47, valued at
$103.7k
|
|
| 04/19/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2021 |
4
| Pande Atul (Director) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 42,000 options to buy
@ $2.47, valued at
$103.7k
|
|
| 04/19/2021 |
4
| Modig Berndt (Director) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 42,000 options to buy
@ $2.47, valued at
$103.7k
|
|
| 04/19/2021 |
4
| Nassif David W. (CFO) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 239,000 options to buy
@ $2.47, valued at
$590.3k
|
|
| 04/19/2021 |
4
| Corcoran Gavin (Chief R&D Officer) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 244,300 options to buy
@ $2.47, valued at
$603.4k
|
|
| 04/19/2021 |
4
| Cheruvu Pavan (CEO) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 682,100 options to buy
@ $2.47, valued at
$1.7M
|
|
| 03/24/2021 |
4
| Cheruvu Pavan (CEO) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Bought 100,000 shares
@ $2.4818, valued at
$248.2k
|
|
| 03/22/2021 |
4
| Nassif David W. (CFO) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 15,060 shares
@ $0
Disposed/sold 15,060 restricted stock units
@ $0 |
|
| 03/19/2021 |
4
| Corcoran Gavin (Chief R&D Officer) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 16,001 shares
@ $0
Disposed/sold 16,001 restricted stock units
@ $0 |
|
| 03/19/2021 |
4
| Cheruvu Pavan (CEO) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Granted 22,590 shares
@ $0
Disposed/sold 22,590 restricted stock units
@ $0 |
|
| 11/25/2020 |
4
| Pande Atul (Director) has filed a Form 4 on Sio Gene Therapies Inc.|
Txns:
| Bought 10,000 shares
@ $2.3399, valued at
$23.4k
|
|
| 10/07/2020 |
4
| Vuori Kristiina MD (Director) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 35,000 options to buy
@ $5.63, valued at
$197.1k
|
|
| 10/07/2020 |
3
| Vuori Kristiina MD (Director) has filed a Form 3 on Axovant Gene Therapies Ltd. |
| 07/10/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/10/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/15/2020 |
4
| Nassif David W. (Principal Financial Officer) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 15,060 shares
@ $0
Paid exercise price by delivering 5,266 shares
@ $3.25, valued at
$17.1k
Disposed/sold 15,060 restricted stock units
@ $0 |
|
| 06/15/2020 |
4
| Cheruvu Pavan (Principal Executive Officer) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 22,591 shares
@ $0
Paid exercise price by delivering 9,755 shares
@ $3.09, valued at
$30.1k
Disposed/sold 22,591 restricted stock units
@ $0 |
|
| 06/15/2020 |
4
| Corcoran Gavin (Chief R&D Officer) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 16,002 shares
@ $0
Paid exercise price by delivering 6,211 shares
@ $3.46, valued at
$21.5k
Disposed/sold 16,002 restricted stock units
@ $0 |
|
| 04/17/2020 |
4
| Modig Berndt (Director) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 17,500 options to buy
@ $3.45, valued at
$60.4k
|
|
| 04/17/2020 |
4
| Pande Atul (Director) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 17,500 options to buy
@ $3.45, valued at
$60.4k
|
|
| 04/17/2020 |
4
| Torti Frank (Director) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 17,500 options to buy
@ $3.45, valued at
$60.4k
|
|
| 04/17/2020 |
4
| Sundaram Senthil Vel (Director) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 17,500 options to buy
@ $3.45, valued at
$60.4k
|
|
| 04/17/2020 |
4
| Corcoran Gavin (EVP of R&D) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 63,700 options to buy
@ $3.45, valued at
$219.8k
Granted 42,400 restricted stock units
@ $0 |
|
| 04/17/2020 |
4
| Nassif David W. (Principal Financial Officer) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 78,900 options to buy
@ $3.45, valued at
$272.2k
Granted 52,600 restricted stock units
@ $0 |
|
| 04/17/2020 |
4
| Cheruvu Pavan (Principal Executive Officer) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Granted 169,100 options to buy
@ $3.45, valued at
$583.4k
Granted 112,700 restricted stock units
@ $0 |
|
| 03/18/2020 |
4
| Pande Atul (Director) has filed a Form 4 on Axovant Gene Therapies Ltd.|
Txns:
| Bought 10,000 shares
@ $1.7844, valued at
$17.8k
|
|
| 02/27/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|